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Abstract
Background: Ovarian cancer is the leading cause of mortality from gynecological malignancies, often
undetectable in early stages. The difficulty of detecting the disease in its early stages and the propensity of ovarian
cancer cells to develop resistance to known chemotherapeutic treatments dramatically decreases the 5-year
survival rate. Chemotherapy with paclitaxel after surgery increases median survival only by 2 to 3 years in stage
IV disease highlights the need for more effective drugs. The human immunodeficiency virus (HIV) infection is
characterized by increased risk of several solid tumors due to its inherent nature of weakening of immune system.
Recent observations point to a lower incidence of some cancers in patients treated with protease inhibitor (PI)
cocktail treatment known as HAART (Highly Active Anti-Retroviral Therapy).
Results: Here we show that ritonavir, a HIV protease inhibitor effectively induced cell cycle arrest and apoptosis
in ovarian cell lines MDH-2774 and SKOV-3 in a dose dependent manner. Over a 3 day period with 20 μM
ritonavir resulted in the cell death of over 60% for MDAH-2774 compared with 55% in case of SKOV-3 cell line.
Ritonavir caused G1 cell cycle arrest of the ovarian cancer cells, mediated by down modulating levels of RB
phosphorylation and depleting the G1 cyclins, cyclin-dependent kinase and increasing their inhibitors as
determined by gene profile analysis. Interestingly, the treatment of ritonavir decreased the amount of
phosphorylated AKT in a dose-dependent manner. Furthermore, inhibition of AKT by specific siRNA
synergistically increased the efficacy of the ritonavir-induced apoptosis. These results indicate that the addition of
the AKT inhibitor may increase the therapeutic efficacy of ritonavir.
Conclusion: Our results demonstrate a potential use of ritonavir for ovarian cancer with additive effects in
conjunction with conventional chemotherapeutic regimens. Since ritonavir is clinically approved for human use
for HIV, drug repositioning for ovarian cancer could accelerate the process of traditional drug development. This
would reduce risks, limit the costs and decrease the time needed to bring the drug from bench to bedside.
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Background
Ovarian cancer is the second most common gynecologic
malignancy, but the most common cause of death among
women who develop gynecologic cancers [1]. It is the fifth
leading cause of cancer death in females in the United
States. It is estimated that 22,430 new cases along with
15,280 deaths were attributed to ovarian cancer in 2007
in the United States [1]. Although current management
strategies have resulted in a several fold increase in the
median survival for ovarian cancer over past few decades,
mortality from the disease still remains high [2]. Up to
one third of the patients who receive the first line plati-
num based chemotherapy for ovarian cancer fail to
achieve clinical remission and approximately 50%
patients who achieve clinical remission in first course of
chemotherapy, eventually have relapse of their disease[2].
Both of the above mentioned categories of patients have
exceedingly poor 5 year survival rates indicating the need
to develop novel chemotherapeutic drugs which could
find their use either as sole therapy or in combination
with already existing drugs.
The HIV (human immunodeficiency virus) infection is
characterized by inherently increased risk of multiple
blood and solid organ malignancies. Highly Active Anti-
Retroviral Therapy (HAART) is the term used for intensive
combination therapy used to treat patients with HIV
infection. The combination typically consists of reverse
transcriptase inhibitors (e.g. Zidovudine) and protease
inhibitors (e.g. ritonavir, nelfinavir). Use of HAART has
resulted in substantial reductions in progression of HIV to
AIDS, reduction in opportunistic infections, hospitaliza-
tions, and deaths [3]. Interestingly, recent observations
point to a decreasing incidence of neoplastic lesions in
patients using HAART. [4-6] In the Swiss HIV Cohort
Study Clifford et. al., [7] reported that in HAART users, the
standardized incidence ratio for Kaposi Sarcoma
decreased to 25.3 (95% CI = 10.8 to 50.1) as compared to
239 (95% CI = 211 to 270) in non HAART users. Many
other investigators have subsequently reported similar
associations of potential anti-neoplastic impact of
HAART. [8-10] Even before the above mentioned studies
were published, the anti-neoplastic properties of ritonavir
(which is a protease inhibitor and forms an integral part
of HAART), had already been demonstrated in some can-
cers. Specifically, Ritonavir induced apoptosis in tumor
cell lines of lymphoblastoid origin, including lymphoma
cells and myeloid leukemia cells, fibrosarcoma and mas-
tocytoma cells as well as immortalized Kaposi's-sarcoma
cell lines [11,12]. No effect on proliferation or survival
was observed with non-tumor cells, including non-trans-
formed immortalized fibroblasts or primary macrophages
[13,14].
PI3K/AKT pathway is an important regulator of cellular
proliferation and survival, and plays a central role in the
progression and metastasis of various human cancers
[15,16]. This pathway is activated in wide range of tumors
but not in normal tissues. We hypothesize that the inhibi-
tion of this pathway with RNAi together will ritonavir
treatment may offer better tumor regression. RNAi is an
innate gene-silencing mechanism evolved to protect
against viruses initiated by 19 bpl double-stranded RNA
molecules (short interfering RNA) homologous to the
sequence of the target gene that mediate post-transcrip-
tional gene-silencing [17,18]. Introduction of chemically
synthesized siRNAs can mimic gene silencing target genes.
Loss of function studies can be done using siRNA technol-
ogy for any given gene to assess the function of a gene.
The objective of the current study is to assess the anti-neo-
plastic impact of ritonavir, and to delineate the underly-
ing mechanisms. Development of clinically approved HIV
drug, ritonavir as an effective adjuvant therapy in ovarian
cancer by drug repositioning could accelerate the process
of traditional drug development in oncology.
Results
Ritonavir acts as antiproliferating agent for ovarian cancer 
cell lines
We tested the cytotoxicity of the drug ranging from 5–100
μM on MDAH- 2774 and SKOV-3 ovarian cancer cell lines
over 3 days exposure. A dose dependent inhibition of cell
proliferation in both the cell lines was observed as shown
(Fig. 1A &1B). Over a 3 day period with 20 μM ritonavir
resulted in the cell death of over 60% for MDAH-2774
compared with 55% in case of SKOV-3 cell line. Further
we tested if ritonavir can enhance the cytotoxicity of pacl-
itaxel which is commonly used for the treatment of ovar-
ian cancers. MDAH-2774 cells were tested with paclitaxel
over 4 day period with and without ritonavir. Approxi-
mately 1 μM paclitaxel resulted in 40% cell death in 3 day
period. We observed a time dependent decline in survival
of MDAH-2774 cells in combination experiments with 10
μM ritonavir. With 1 μM paclitaxel and 10 μM ritonavir
resulted in over 50% cell death in 2 day period in compar-
ison with 20 μM ritonavir alone which takes 3 days to kill
50% of the cells (Fig. 1C). The data clearly indicates that
ritonavir can significantly enhance effect of paclitaxel in
ovarian cancer cells. Further the extent of cell death with
ritonavir increased a function of time in all the tested
doses ranging from 1 to 100 μM in 48 h as observed by
phase contract microscopy in MDAH-2774 cell line (Fig.
1D).
Ritonavir induces apoptosis MDAH-2774 cells
Annexin V is a Ca2+ dependent protein with high affinity
for membrane phospholipids [19] that has been used to
identify apoptotic cells and has been validated in the liter-
ature. Control and treated cells were prepared for bivariate
analysis using fluorescence-activated cell sorter system
(FACS). We observed that the ratio of late apoptotic cells
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increased with the increased dose of ritonavir treatment:
approximately 8% with 15 μM treatment and 20% with
25 μM treatment for 48 h as compared to early apoptosis,
which increased from 9% to 36% (Fig. 2A). Further as
analyzed by the fluorescent microscope after 48 h expo-
sure to ritonavir, 80% of the cells stained positive for
annexin V, whereas controls were less than 5% annexin V
positive (Fig. 2B).
Ritonavir enhances pro-apototic signals while inhibiting 
anti-apotitic bcl-2 expression
The balance between pro and anti-apoptotic signals
decides the fate of the cells and therefore we examined the
expression levels of genes that are involved in the apop-
totic pathway by western blot analysis. Approximately 10
fold increase in the expression of p53 was observed by
western blot analysis in the same samples (Fig. 3). Pri-
mary cellular function of Poly (ADP-ribose) polymerase-
1 (PARP) is not entirely certain, never the less it plays an
important role in apoptosis as a cellular response to
chemotherapeutic and DNA damaging agents [20]. PARP
cleavage is an indirect way of semi-quantitative measure-
ment of the activated caspase-3 and a direct measurement
of the extent of the apoptosis. Western blot analysis
revealed dose dependent activation of the caspase-3 as
determined by its cleavage of PARP. Treatment for 48 h
resulted in a dose-dependent cleavage of the 117-kDa
PARP to the smaller 85-kDa product. Cleavage was first
seen at 15 μM of ritonavir, with further increases in the
levels of the 85-kDa cleavage product seen with 25 μM. A
Effect of ritonavir on the growth of ovarian cancer cell linesFigure 1
Effect of ritonavir on the growth of ovarian cancer cell lines. MDAH-2774 cells (A) and SKOV-3 cells (B) were cul-
tured for indicated times at various concentrations of the ritonavir. Cell growth was assessed by CCK-8 cell proliferation assay 
method and is expressed as a percentage of control (DMSO treated cells) and represents the mean of triplicate cultures. C. 
MDAH-2774 cells were incubated with either 15 μM ritonavir (RTV) or 1 μM paclitaxel (PAC) or both and cultured for 4 days. 
Data is representation of three independent experiments. D. MDAH-2774 cells were incubated with indicated RTV concentra-
tions for 48 hrs and were photographed under a phase contrast microscope. Representative fields of two independent experi-
ments are shown.
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dose-dependent increase in the expression of the pro-
apoptotic protein Bak with concomitant inhibition of
anti-apoptotic protein Bcl-2 was also observed (Fig 3).
Ritonavir causes cell cycle arrest and blocks S phase entry 
of MDAH-2774 cells in cultures
Ritonavir induced G2/M arrest in a dose-dependent man-
ner (Fig. 4A, B and 4C) in MDAH-2774 but not in normal
human fibroblasts (data not shown). Remarkably, the
proportion of cells in the G0/G1 phase arrest increased
from 48.8% to 89.2% while S phase of cells decreased
from 28.7% to 3.3% with the treatment of 20 μM ritonvir
within 24 hrs (Fig. 4A, B and 4C). Further we observed
dose dependent inhibition in the S phase cells indicative
of the inhibition of DNA synthesis in MDAH-2774 cells in
dose dependent manner.
Analysis of apoptotic cellsFigure 2
Analysis of apoptotic cells. Apoptotic cells were analyzed by using Annexin V FITC apoptosis ditection kit (Calbiochem, 
Gibbstown, NJ). A. Control and itonavir (15 and 25 μM) treated MDAH-2774 cells (1 × 105 cells) were fixed stained both with 
Annexin V FITC and with propidium iodide (20 μg/ml) were processed for flow cytometric analysis. A flow cytometer emitting 
an excitation light at 488 nm was used to quantify the Annexin V-FITC and propidium iodide signals. Log of FITC signal repre-
sented on X axis and log of propidium iodide fluorescence signals were plotted on Y axis. B. MDAH-2774 cells were mixed 
with annexin V-biotin, incubated for 15 min at room temperature, and treated with streptavidin conjugated to FITC. Apoptotic 
cells within the same microscopic field were viewed and photographed by phase contrast and by fluorescence emitted at 518 
nm (FITC filter) were taken. Using the FITC filter, early apoptotic cells (positive for Annexin V-Biotin-FITC staining) appear 
bright green.
Phase contrast Annexin V
Control
25 M RTV
Control 15 M RTV 25 M RTV
A
B
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Ritonavir mediated perturbations in cell cycle regulatory 
proteins
Since we observed a significant increase in the population
of G0/G1 phase of the cells with the treatment of ritona-
vir, we evaluated genes that control the cell cycle progres-
sion at G0/G1 phase. The cell cycle progression at G0/G1
phase is inhibited by active under-phosphorylated form
retinoblastoma protein (RB) which sequesters growth
promoting E2F-1 transcription factor. To evaluate if the
observed block of S phase entry is due to the activation of
RB protein, we first analyzed the levels of phosphoryla-
tion of RB and expression of E2F-1 by western blot analy-
sis. We observed inhibition of phosphoryation status of
the RB in response to ritonavir in dose dependent manner
compared with control along with decrease in the E2F-1
protein levels (Fig. 5A). Gene expression analysis of RB
and its related tumor suppressor proteins revealed an
increase of 1.44 folds in the RB expression and 1.30 folds
of p107 expression but there is decrease in the expression
of p130 by 1.1 folds (Fig. 5B). Further we analyzed expres-
sion levels of three of the E2F family of proteins, E2F-1, 2
and 3 which interact with RB and as expected we observed
1.53 fold, 3.05 folds and 1.05 folds reduction in the
expression levels of E2F-1, 2 and 3 respectively (Fig. 5C).
Cyclins and cyclin dependent kinases (CDKs) exhibit dis-
tinct expression patterns which contribute to the temporal
coordination of each event in cell cycle progression. G1
phase of cell cycle is regulated mainly by cyclin D, E and
CDK2, 4 and 6. Ritonavir treatment resulted in the
decreased expression levels of G1 phase cyclins and CDKs
corroborating inactivation of RB proteins (Fig. 5D and
5E). Further we observed increased expression cyclin
dependent kinase inhibitors (CDKIs) which bind and
inhibit the activity of cyclin/Cdk complexes and nega-
tively regulate cell cycle progression (Fig. 5F).
Ritonavir inhibits AKT pathway leading to apoptosis in 
MDAH-2774 cells
AKT, plays a critical role in controlling the balance
between survival and apoptosis and plays a significant
role in insulin stimulation of glucose transport[21]. Ear-
lier work with protease inhibitors showed inhibition of
AKT in breast and hematological malignancies [22-24].
We tested if ritonavir inhibited AKT signaling in ovarian
cancer cell lines using synthetic siRNA as known inhibitor
for AKT. We found that ritonavir was more efficacious in
decreasing phosphoryated AKT than siRNA. Significant
reduction in the expression of AKT was also observed
transfected with siRNA, compared with scrambled siRNA
transfected control cells. Furthermore ritonavir has syner-
gistic effect on reducing AKT expression when treated
together AKT siRNA. In addition, the suppression of AKT
both ritonavir treatment and AKT siRNA decreased the
expression of anti-apoptotic Bcl-2 expression (Fig. 6A).
Further we observed a dose dependent decrease in the
Hsp90 levels with ritonavir treatment. Heat shock protein
90 (Hsp90) binds to AKT and protects it from being inac-
tivated by protein phosphatase 2A-mediated dephospho-
rylation (Fig. 6B).
We next examined the effect of the inhibition of AKT
expression on cell proliferation and apoptosis in ritona-
vir-treated MDAH-2774 cells. In order to investigate the
possible additive effects of the inhibition of cell prolifera-
tion by AKT siRNA and ritonavir, we chose lower doses for
the treatment. Ritonavir at 5 μM inhibited cell prolifera-
tion by approximately 20% but the cell death was dramat-
ically increased to 60% when it was combined with 100
nM AKT siRNA. AKT siRNA transduction by itself inhib-
ited the cell proliferation by approximately 15% (Fig. 7A).
In order to further confirm our findings of involvement of
AKT pathway with ritonavir treatment, serial treatments
with IGF-1 (known AKT stimulator) and LY294002
(known inhibitor of AKT/PIK) pathway were carried out.
When exposed to IGF-1, cell growth was increased by over
30%. Exposure of ritonavir down regulated the IGF-1
Analysis apoptosis related proteins with the treatment of ritonavirFigure 3
Analysis apoptosis related proteins with the treat-
ment of ritonavir. MDAH-2774 cells treated with 15 μM 
ritonavir for 48 h were harvested and cell lysate was pre-
pared. Approximately 10 μg of total cell extracts of control 
and ritonavir treated MDAH-2774 cells were resolved by 
SDS-PAGE, transferred to nitrocellulose membrane; and 
probed with PARP, Bcl-2, Bak and p53. β actin was used as a 
loading control. Native and cleaved PARP are indicated by 
arrows.
Bak
Bcl-2
E actin
0
p53
PARP native
PARP cleaved
15
PM
25
PM
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induced growth of the cells. We further observed that the
AKT siRNA inhibition of IGF-1 induced cell growth was
more pronounced than ritonavir (Fig. 7B). As expected,
treatment with IGF-1 antagonized the effects of ritonavir
and anti-AKT siRNA, whereas treatment with LY294002
potentiated the effects of ritonavir and anti-AKT siRNA
(Fig. 7C).
Ritonavir inhibits cell motility and invasiveness
Cell migration and invasiveness are directly related to
metastasis. We determined migration of MDAH-2774
cells in a modified Boyden chamber. Cells migrated
through membranes covered with matrigel from upper
chamber with various ritonavir concentrations to a lower
chamber filled with medium only. We observed a progres-
sive decrease in the cell migration through membrane
with the ritonavir treatment from up to 20 μM. Treatment
with 15 μM ritonavir decreased the cell invasion through
the matrigel by 50% within 16 hours (Fig. 8). The decrease
in the migration did not appear to be due to cytotoxicity
since ritonavir (15 or 20 μM) showed no inhibitory effect
on cell proliferation in 16 hr as determined by cytotoxic
assay (data not shown).
Discussion
Finding new indications for the already existing com-
pounds, called drug repositioning that takes advantage of
the existing data on pharmacokinetics, toxicity and dosage
escalation studies in humans. Drug repositioning can
potentially have tremendous cost savings and can expe-
dite movement of a drug from bench to bedside in a rela-
tively short amount of time [25]. For example
lenalidomide, an analogue of thalidomide was originally
marketed for morning sickness that is now 'repositioned'
and approved for therapy of multiple myeloma [26]. This
is a prime example of the immense potential of drug repo-
sitioning. Likewise oral hypoglycemic rosiglitazone [27],
immunosuppressant drug rapamycin [28], and the birth
control hormone medroxy-progesterone acetate [29] are
also being tested for 'repositioning' to be used as anti-can-
cer agents. Ritonavir is an FDA approved drug for HIV
treatment, being used well over a decade with tolerable
side effects [30].
Ovarian cancer is the deadly form of gynecologic malig-
nancy with exceedingly poor 5 year survival rates [2] and
is the subject of intense research for development of
newer antineoplastic compounds which could be used
either as a sole or adjuvant therapy. Further, newer com-
pounds may hold even greater promise in drug resistant
and relapsing ovarian cancer where the efficacy of the
existing chemotherapeutic agents is marginal, at best.
Here for the first time, we show that ritonavir acts as an
effective anti-proliferating agent for the ovarian cancers
cells in vitro by inducing growth arrest and apoptosis pro-
viding insights into molecular mechanisms. Further, it
also exhibits the potential to inhibit invasion and migra-
tion of these cell lines. Although paclitaxel and carbopla-
tin have good response rates, there are limited treatment
options in case of disease relapse where majority of
patients become refractory to conventional chemotherapy
Effect of ritonavir on DNA synthesis of MDAH-2774 cellsFigure 4
Effect of ritonavir on DNA synthesis of MDAH-2774 cells. MDAH-2774 and normal human fibroblasts were seeded at 
106 cells and grown serum-free medium for 48 h for cell cycle synchronization. The cells were then treated with either vehicle 
DMSO (A) or 5 μM ritonavir (B) or 20 μM ritonavir (C). Cells were further incubated in presence of serum for 24 h followed 
by fixation, staining and cytometric analysis using Cell cycle phase determination kit (Cayman chemical company, Ann Arbor, 
MI).
Propidium Iodide
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due to the generation of drug resistant phenotype [31]. In
addition we document an additive effect of cell killing
when ritonavir combined with paclitaxel.
Retinoblastoma protein (RB) is an important tumor sup-
pressor protein that control progression through the late
G1 phase of the cell cycle and, thereby, the commitment
to enter the S phase[32,33] Also, E2F-1 transcription fac-
tor that is necessary t o drive the cell into S
phase.[32,34,35] Cyclins and cyclin-dependent kinases
(CDKs) regulate the activity of RB by phosphorylation
that controls the progression through G1 [34-36]. Since
we observed elevated levels of under-phosphorylated RB,
we speculated the lower levels of CDK-2, 4 and 6, one of
the important proteins responsible driving cell cycle pro-
gressions through G0/G1 phase of cell cycle by phospho-
rylation of RB. As expected, gene profile analysis of
ritonavir treated cells showed down modulation of CDKs
and cyclins that are gate keepers of G0/G1 phase of cell
cycle. The p21WAF-1/Cip1 inhibits CDK-4, thus prevent-
ing both phosphorylation of RB and the release of tran-
scriptionally active E2F-1. Our observations of lower
levels of CDK inhibitors and inhibition of RB phosphor-
ylation along with increased levels of expression of E2F-1
Analysis of cell cycle regulatory proteinsFigure 5
Analysis of cell cycle regulatory proteins. A. Approximately 10 μg of protein extracts of control and 5 μM and 20 μM 
ritonavir treated MDAH-2774 cells for 48 h were resolved by SDS-PAGE, transferred to nitrocellulose membrane; and probed 
with RB and E2F-1. β actin was used as a loading control. RB-p: hyper phosphorylated retinoblastoma protein; RB: Under phos-
phorylated retinoblastoma protein. MDAH-2774 cells treated with 15 μM ritonavir for 48 h were harvested and total RNA 
was isolated to generate cRNA and was hybridized to Whole Human Genome (G4112A) arrays (Agilent Technologies, Santa 
Clara, CA) according to the manufacturer's protocol. B. Analysis of RB family of pocket proteins. C. Analysis of E2F family of 
transcription factors. D, E and F represent the gene profile analysis of the expression of CDKs and Cyclins and CDKIs respec-
tively that are involved in G0 to G1 phase transition.
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transcription factor in response to ritonavir corroborate
the results of cell cycle analysis where cells entering S-
phase were reduced by over 25%.
Numerous studies show that the PI3K/AKT pathway is
constitutively over-expressed in ovarian cancers, apart
from several other common human cancers [37]. Activa-
tion of AKT is a key event in producing chemo-resistant
phenotype through a variety of pathways [38], whereas
inhibition of AKT sensitizes chemo-resistant cells to cispl-
atin induced apoptosis. Our data corroborates with the
observations that increased levels of AKT contributes to
chemo-resistance by attenuating p53-mediated PUMA up-
regulation and phosphorylation of p53, which are essen-
tial for sensitivity to cisplatin-induced apoptosis [39]. Our
data indicated that ritonavir inhibits phosphorylation of
AKT followed by effective apoptosis. Taken together, these
findings suggest that ritonavir may have useful role as an
anti-AKT agent in treatment of ovarian cancer in general,
but more specifically in relapsed patients due to drug
resistance phenotype generation which is attributed to
AKT. Further, the Bcl-2 inhibition appeared to be medi-
ated through an AKT dependent pathway, as treatment of
anti-AKT siRNA had similar results as ritonavir in Bcl-2
down regulation.
One of the important reasons for high mortality in ovar-
ian cancer patients is the late stage at which the disease is
diagnosed, namely FIGO III [40], where tumor cells
would have already traversed the peritoneal cavity by
migration and invasion. Effect of ritonavir in inhibiting
the invasion and migration of the ovarian cancer cell lines
adds another dimension in its anticancer properties and
may be especially useful in ovarian cancer as trans-perito-
neal spread is a key event in this cancer. We are currently
studying the precise molecular pathways involved in
migration inhibition seen with ritonavir in in-vivo models.
Ritonavir has been in use for over a decade in the treat-
ment of HIV patients with acceptable toxicity profiles, the
primary impetus for this work has been to evaluate the re-
positioning of the drug to ovarian cancer chemotherapy.
An important aspect of repositioning of ritonavir from
HIV therapy to cancer therapy will be the achievable dose
in cancer patients. Ritonavir blood plasma levels in HIV
patients normally observed at 15 μM [41] and much
higher concentrations of over 45 μM were also observed
in individual patients [41,42]. We observed the growth
inhibitory effects of ritonavir in ovarian cancer patients in
the range of 5 to 20 μM which is lower than the plasma
concentrations observed in HIV patients.
Studies to further elucidate mechanism, specifically cell
signaling target modulation, are ongoing in our lab. The
determination of synergistic or additive effects in conjunc-
tion with conventional chemotherapeutic regimens repre-
sents a putative application for ritonavir at its so far
known non-toxic concentrations. This would accelerate
the process of drug development for a disease that has
highest mortality rate among gynecological cancers.
Conclusion
Ovarian cancer poses many treatment difficulties as it is
often undetectable in its early stages, and therefore diag-
nosis usually occurs when surgical treatment is no longer
an effective option emphasizing the need for novel, non-
toxic and effective treatments. Here we present the evi-
dence that ritonavir; an FDA approved drug for human
use for HIV effectively induces cell cycle arrest and apop-
tosis by inhibiting AKT pathway and retinoblastoma
phosphorylation. Further we observed an additive effect
of ritonavir in killing ovarian cancer cells when used in
conjunction with paclitaxel showing its potentials to be
'repositioned' for ovarian cancer as an adjuvant therapy.
Materials and methods
Reagents and antibodies
Ritonavir was obtained from Sequoia Research Products
Limited (Pangbourne, UK) and dissolved in dimethyl sul-
foxide (DMSO). Stock solutions were freshly prepared in
DMSO (0.001%) and added to the cell cultures to obtain
the indicated final concentrations. DMSO alone
(0.001%) was found to have no significant effect on cellu-
lar function. Following antibodies were used: Retinoblas-
toma & E2F-1 antibodies from Millipore (Danvers, MA);
Cyclins, CDKs, poly (ADP-ribose) polymerase (PARP)
and actin antibodies from Santa Cruz Biotechnology,
(Santa Cruz, CA). Antibodies against phospho-AKT, cas-
Wester blot analysis of AKT siRNA treated MDAH-2774 cellsFigure 6
Wester blot analysis of AKT siRNA treated MDAH-
2774 cells. A. Approximately 10 μg of protein extracts of 
control and treated samples of MDAH-2774 cells as indi-
cated were resolved by SDS-PAGE, transferred to nitrocellu-
lose membrane; and probed with Bcl-2. β actin was used as a 
loading control. B. SDS-PAGE analysis of ritonavir treated 
samples of MDAH-2774 cells.
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pases, Insulin like growth factor 1 (IGF-1) were obtained
from Cell Signaling Technology (Beverly, MA). SignalSi-
lence AKT siRNA inhibition kits were purchased from Cell
Signaling Technology (Beverly, MA).
Cell lines and culture
Ovarian cancer cell lines, MDAH-2774 and SKOV-3
(American Type Culture Collection, Manassas, VA) were
propagated in McCoy's 5A medium and normal human
fibroblasts were propagated in DMEM medium, both
were supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 units/ml penicillin, and 100 μg/ml
streptomycin (ThermoFisher Scientific, Pittsburgh, PA).
Cells were cultured in a humidified atmosphere with 5%
CO2 at 37°C. Trypsin (0.25%)/EDTA solution was used
to detach the cells from the culture flask for passing the
cells.
Cell proliferation assays
Standard prototype growth curves and number of viable
cells were determined for each cell line (treated and con-
trol groups) in triplicate experiments by the Cell Counting
Kit-8 (CCK-8) (Dojindo, Gaithersburg, MD) according to
manufactures' instructions. Briefly, cells were plated at a
density of 3,000 per well in 96-well plates in a total of 100
μl medium and allowed to grow for 24 h. Ritonavir dis-
solved in DMSO was added, and the cells were allowed to
grow for the indicated time. Growth of the cells in each set
Effect of AKT siRNA, ritonavir and modulators of AKT signaling on the growth of ovarian cancer cell linesFigure 7
Effect of AKT siRNA, ritonavir and modulators of AKT signaling on the growth of ovarian cancer cell lines. 
Cells were cultured for indicated time points with various concentrations of the ritonavir. Cell growth was assessed by CCK-8 
cell proliferation assay method and is expressed as a percentage of control (DMSO treated cells) and represents the mean of 
triplicate cultures. (R-ritonavir) A. Effect of ritonavir, siRNA and in combination; B. Effect of ritonavir and siRNA in presence of 
IGF-1. C. Effect of ritonavir in the presence of AKT inhibitor LY294002.
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of a group was terminated by adding 10 ml of CCK-8 rea-
gent, incubated for an hour and absorbance was read at
450 nm in a plate reader (FluoStar Optima, BMG
Labtech). Growth curves were plotted as a percentage of
the value of DMSO-treated controls minus the value of
untreated cells on day 0. Day 2 & 3 values were considered
for the determination of the 50% cell proliferation inhibi-
tion (IC50) for a given treatment. In some cases parallel
manual count was also performed with trypan blue and
counting by exclusion method using a Hemocytometer.
The findings confirmed CCK-8 assay results. Human
fibroblasts were similarly treated as cancer cells to display
differential cytotoxicity at any given dose.
Analysis of apoptotic cells
Apoptotic cells were analyzed by using Annexin V FITC
apoptosis detection kit (Calbiochem, Gibbstown, NJ).
Ritonavir treated MDAH-2774 cells (1 × 105 cells) were
trypsinized, washed with cold PBS, fixed with 70% etha-
nol, and stored at -20°C until use. The fixed cells were
stained with propidium iodide (20 μg/ml) with RNaseA
(10 μg/ml) and incubated at room temperature for 30
min in the dark. The DNA content of the cells was ana-
lyzed by flow cytometer using the fluorescence-activated
cell sorter system (FACS) and sub G1 population was con-
sidered to represent apoptotic cells. Fluorescence micro-
scope (Zeiss, AXio CamMRm Observer. A1) was used for
visual analysis of apoptotic cells. Propidium iodide (PI)
was added to discriminate early apoptotic cells from late
apoptotic or necrotic cells. For the fluorescent micros-
copy, after incubating the cells with Ritonavir at the indi-
cated dose concentrations for 48 hours, the cells were
trypsinized and washed twice with cold PBS (0.15 mol/L,
pH 7.2). Centrifugation was performed at 5000 c/min for
5 min, and the pellet was resuspended in 1 × binding
buffer at a density of 1.0 × 105 –1.0 × l06 cells per mL. Fur-
ther incubation was performed with 5 μL of FITC-conju-
gated annexin V and 5 μL of PI for 15 min in the dark. 400
μL of 1 × binding buffer was added to each sample tube,
and the samples were analyzed by FACS.
Cell cycle phase determination
MDAH-2774 cells were seeded at 1 × 106 cells in 10 cm
dishes and the culture medium changed to serum-free
medium for 24 h to facilitate cell cycle synchronization.
Cell cycle analysis was conducted using Cell cycle phase
determination kit (Cayman chemical company, Ann
Arbor, MI). Cells were treated with 5 or 20 μM ritonavir
and further incubated in medium containing 10% serum.
Later cells were trypsinized, washed with PBS and re-sus-
pended in 1 ml of assay buffer and 1 ml of fixative both
provided with the kit. After 2 h incubation, cells were cen-
trifuged at 500c for 5 min and cell pellet was retained. Pel-
let was suspended in 0.5 ml of staining solution that
contained PI and incubated for 30 min at room tempera-
ture in the dark. Samples were analyzed in FL2 channel of
flow cytometer with a 488 nm excitation laser.
Western blotting
With 4–15% SDS Tris-Glycine gels, western transfer of
proteins to nitrocellulose papers was conducted with iBlot
dry blotting device (InVitrogen Corp, Carlsbad, CA).
Blocking agent was 3% non fat milk powder and the sec-
ondary antibodies conjugated to HRPO (Santa Cruz Bio-
technology, Santa Cruz, CA) were used. Enhanced
chemiluminescence detection kit from Amersham Phar-
macia, Uppsala, Sweden was used.
Transfection of Akt small interfering RNA (siRNA)
SignalSilence AKT siRNA inhibition kit (Cell Signaling
Technology Beverly, MA) that specifically inhibits the
expression of both AKT 1 and AKT 2, was utilised to
downregulate AKT protein in MDAH-2774. Briefly,
MDAH-2774 cells were transfected with 100 nM siRNA
with the transfection reagent provided in the kit. Cells
were harvested after 48 hrs and analyzed for the expres-
sion of AKT, Bcl-2 and actin antibodies. Controls were
transfected with non-specific SiRNA and grown under
similar conditions. Similar to SiRNA, inhibition of AKT
signaling was achieved by LY294002 whereas forced
induction of the Akt pathway was achieved by IGF-1 treat-
ment. The treatment with AKT SiRNA, IGF-1 and
LY294002 was conducted to investigate the AKT/PIK path-
way involvement in Ritonavir treatment of cell cultures.
In vitro migration and wound-healing Assays
Cell migration was determined with a modified Boyden
chamber assay with filters of 8-μm pore size were used.
Briefly, MDAH-2774 cells (105/500 μL) were added into
Analysis of cell migration and invasionFigure 8
Analysis of cell migration and invasion. MDAH-2774 
cells were cultured for 24 h, trypsinized and seeded in 
boyden chambers and treated with various concentrations of 
ritonavir as described in methods. Migrated cells through the 
membrame with different concentrations of ritonavir were 
stained and counted under microscope. Results of three 
independent experiments were plotted.
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the upper compartment of a migration chamber with var-
ious concentrations of ritonavir. The chamber was then
incubated at 37°C in a 5% CO2. After 18 h, the non-
migrated cells on the upper surface of the membrane were
removed using cotton buds. The underside of the cham-
ber was washed twice with in PBS, fixed by 4% formalde-
hyde for 20 min and stained by DIPA or crystal violet
(0.1% w/v) for 15 min. The number of migrated cells at
other side of the compartment was counted under a
microscope for nine random fields. The assays were per-
formed in triplicate. For wound healing assays, MDAH-
2774 cells were plated at equal density in and grown to
80% confluency. Using a sterile pipette tip, wounds were
generated. Cells were then rinsed with medium and
replaced with the fresh medium. Areas of wound were
marked and photographed at various time points with a
phase-contrast microscope.
Gene Expression Profiling
MDAH-2774 cells treated with 15 μM ritonavir for 24 h,
were harvested and total RNA was isolated utilizing an
RNeasy kit (Qiagen Inc., Valencia, CA), reverse-tran-
scribed to get cDNA using the "Superscript II RT kit" (Inv-
itrogen™ Life Technologies, Carlsbad, CA). cDNA was
used in an in vitro transcription reaction to synthesize
cRNA utilizing "ENZO RNA labeling kit (Enzo Diagnos-
tics, Inc., Farmingdale, NY). Labeled cRNA was purified
with the RNeasy Mini-kit (Qiagen Inc., Valencia, CA) and
quantitated. Purified cRNA (15 μg) was hybridized to
Whole Human Genome (G4112A) arrays (Agilent Tech-
nologies, Santa Clara, CA) according to the manufac-
turer's protocol. The G4112A set consists of arrays
representing approximately 44,000 human genes. Total
RNA was amplified using Agilent Low Input Linear Ampli-
fication Kit according to the process outlined by the man-
ufacturer (Agilent Technologies, Santa Clara, CA).
Amplified target cRNA (1–5 μg) was labeled with either
cyanine-5 or cyanine-3 using ULS RNA Flurorescent Labe-
ling Kit according to the manufacturer's protocol
(Kreatech Biotechnology, Amsterdam, The Netherlands).
Concentration of labeled cRNA and the label incorpora-
tion was determined by Nanodrop-1000 spectrophotom-
eter. Labeled cRNA was fragmented and hybridized
overnight to Agilent whole Human Genome arrays (4 × 44
K format) according to Agilent protocol. The arrays were
scanned using Agilent scanner (G2505B) and data was
extracted using Agilent's Feature Extraction Software.
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